BIRC5 and osteosarcoma: Dual silencing of the VEGF and Survivin genes effectively inhibited the proliferation, migration, angiogenesis and survival of the osteosarcoma cells [117], suggesting a potential of VEGF pathway blockade as another therapeutic maneuver to salvage T cell immunotherapy against osteosarcoma.